Letter : Human genes: patently not the case
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.From Mr Adrian Brasnett
Sir: It is incorrect to suggest in your article "MEPs reject gene patenting" (2 March) that the decision of the European Parliament to reject the European Biotechnology Directive marks an end to the possibility of securing patent protection in Europe for human genes or cells. The European Patent Office (a non-EU body to which all EU members subscribe) has granted several patents relating to human genes and, indeed, recently upheld such a patent despite a legal challenge that it was unethical.
The EPO decides whether a gene can be patented on the basis of criteria which are applied to all types of invention, namely whether it is new, not obvious and has a practical use. The origin of the ill-fated Directive lay in part as a response to concerns that different or additional criteria should apply to the patenting of human genes, in particular moral criteria.
Although the EPO may also refuse patents on moral grounds, it has declined to do so where the invention relates to technologies that are both permitted and tightly regulated by other laws in member states. It is probably right in the long term that all inventions be assessed by the same criteria for patentability. These criteria can be traced back to the first UK patent law of 1624 and have been able to accommodate 20th-century industries in electronics and pharmacy.
The EPO has proved capable of determining the patentability of biological inventions without the need of a special Directive from Brussels, and this does provide some level of certainty for industry, which would have faced further confusion had the Directive been passed.
Yours faithfully
ADRIAN BRASNETT
London, N16
2 March
The writer is a Patent Attorney specialising in biotechnology.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments